Oruka Therapeutics’ Post

Antibody Therapeutics just published a new interesting review article. This article provides an overview of Connexin 43 hemichannels, elucidating their crucial involvement in various diseases and outlining potential therapeutic strategies, including antibody-based interventions. Furthermore, this review lays the groundwork for advancing novel therapeutic approaches that could significantly impact patient care. The three authors of this article are Yanfeng Zhang at AlaMab Therapeutics Inc, Francisca Acosta and Jean Jiang at UT Health San Antonio. Open access to this new paper at: https://lnkd.in/g3Dti8Y3 Chinese Antibody Society and its official journal, Antibody Therapeutics jointly organize 2024 mAbTalk Symposium on December 15 in San Diego with the theme of “AntibodyPlus - Bispecific Antibodies and Antibody-Drug Conjugates”. You are welcome to know more information about this symposium and register for it via the following link. https://lnkd.in/gjCEAVxM #antibodies #antibody #antibodytherapeutics #mabs #mab

Targeted immuno-oncology therapeutics, such as immune cell engagers and CAR-T therapies, are influenced by receptor expression levels, which are a crucial factor. Therefore it is essential to establish the correlation between target antigen density and the effectiveness of these therapeutic methods. With the introduction of the FDA Modernization Act 2.02 , advocating for reduced animal model use, there is an additional motivation for deploying more cost-effective human in vitro models that can be implemented earlier in the drug discovery process. In this application note, Antibody Analytics (Motherwell, UK) integrates IndEx-2, an advanced in vitro cell-based platform, engineered to modulate the expression of one or two target antigens across a range of biologically relevant levels, with the Agilent xCELLigence Real-Time Cell Analyzer (RTCA), Agilent NovoCyte Flow Cytometer, and cytokine release measurement protocols. The aim is to determine the antigen density thresholds required for the activation of potential immunotherapeutic candidates. Read more: https://lnkd.in/dFDFDtuN

Almost 15 years after the first therapeutic antibody received FDA approval, another pioneer in antibody therapeutics came up: Gemtuzumab Ozogamicin (Mylotarg), the first antibody-drug conjugate, first approved in 2000 and reapproved in 2017. 🔬 Antibody type: Humanized IgG4, Antibody-Drug Conjugate (ADC) 💊 Brand name: Mylotarg 🏢 Company: Wyeth Pharmaceuticals, now part of Pfizer, and Celltech 🎯 First indication: Acute myeloid leukemia (AML) Gemtuzumab Ozogamicin revolutionized cancer treatment with its innovative design, combining a monoclonal antibody targeting CD33 with a potent chemotherapy agent, calicheamicin. This ingenious strategy allows for the precise delivery of the cytotoxic drug to leukemic cells, reducing harm to healthy tissues and enhancing therapeutic efficacy. Although initially withdrawn due to safety concerns, Mylotarg was reapproved in 2017. Today, it stands as a pioneer in targeted cancer therapies, offering new hope to patients battling AML. Stay tuned for our next post as we continue to explore more groundbreaking FDA-approved antibodies! #AntibodyOfTheWeek #FDAApproved #MonoclonalAntibodies #CancerTherapy #AML #Biotechnology #MedicalInnovation

Daiichi Sankyo’s (TSE:4568) DATROWAY® (datopotamab deruxtecan) has been approved in Japan for the treatment of adult patients with hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ or IHC 2+/ISH-) unresectable or recurrent breast cancer after prior chemotherapy.  DATROWAY is the first ever TROP-2 directed medicine to be approved in Japan for HR positive, HER2 negative breast cancer and is the second DXd antibody drug conjugate (ADC) approved based on Daiichi Sankyo’s DXd ADC Technology. DATROWAY is the 3rd commercial Trop-2 ADC in the world after Gilead Sciences' Trodelvy® (sacituzumab govitecan-hziy; SG) and Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.’s sacituzumab tirumotecan (sac-TMT, formerly SKB264/MK-2870). Chinese Antibody Society is an independent non-profit, non-government global professional organization with focus upon antibody-based therapeutics. Our society’s official journal, Antibody Therapeutics is an international peer-reviewed, open access journal published by Oxford University Press, and is indexed by ESCI, PubMed and Scopus (2023 CiteScore: 8.7). You are welcome to visit the official website of the journal (see link below) and submit your therapeutic antibody related manuscripts to our journal by June 30, 2025 to enjoy 50% APC (Article Processing Charge/publication fee) discount. . https://lnkd.in/gsTu_U2 #antibodies #antibody #antibodytherapeutics #antibodydiscovery #antibodydevelopment #mabs #mab #biologics

💡 Active proteins for immunotherapy development, specifically targeting the treatment of B-cell malignancies. 🌟 We're delighted to announce a new product, Recombinant CD20 Protein! With a high-quality process and our expertise in membrane proteins, we have developed a protein, meeting the high standards of requirements: ·       Native full-length ·       High purity ·       Fully active conformation ·       High Stability Whether you're exploring novel therapeutics or delving into antibody development, our Recombinant CD20 allows the discovery of new leads (antibody-drug conjugates, specific peptides, monoclonal antibodies, bispecific antibodies…), empowering your research to achieve breakthrough results. Reach out to learn more about how our Recombinant CD20 can elevate your research! 👉 For more detail: https://lnkd.in/deNTYrh6   #EurofinsDiscoverX # EurofinsDiscovery #RecombinantProteins #DrugDiscovery #immunotherapy

Appended bispecific antibody (aBsAb) with two single chain variable fragments (scFv) linked at the c-terminus of its heavy chains is one of the promising formats in bispecific therapeutics. However, the presence of hydrophobic and flexible scFv fragments render aBsAb molecules higher molecule hydrophobicity and structural flexibility, which causes a unique set of challenges in Protein A chromatography purification. To understand more, please check out our latest publication titled "Effects of molecule hydrophobicity and structural flexibility of appended bispecific antibody on Protein A chromatography".

𝐑𝐨𝐮𝐧𝐝𝐮𝐩 𝐨𝐟 #biotech 𝐝𝐞𝐚𝐥𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐟𝐢𝐫𝐬𝐭 𝐡𝐚𝐥𝐟 𝐨𝐟 𝐉𝐚𝐧𝐮𝐚𝐫𝐲 𝟐𝟎𝟐𝟓: 𝐏𝐚𝐫𝐭 𝟏 👇 💰 AbbVie pens $1.05B deal for Simcere Zaiming’s novel trispecific T-cell engager antibody for multiple myeloma. https://lnkd.in/eTMFD9Gi 🤝 Boehringer Ingelheim broadens oncology portfolio with license for Synaffix BV’s ADC technology for up to $1.3B. https://lnkd.in/eQerbGSM 💸 Windward Bio launches with $200M Series A financing to develop anti-TSLP monoclonal antibody for asthma and COPD. https://lnkd.in/e6uFFjpa 💸 Timberlyne Therapeutics launches with $180M Series A financing to advance anti-CD38 monoclonal antibody, for diseases of high unmet medical needs. https://lnkd.in/eHQQn5vy 💰 Daiichi Sankyo US acquires Glycotope ’s anti-TA-MUC1 antibody, gatipotuzumab, for $132.5M. https://lnkd.in/ejUSJreM 💸 Ouro Medicines launches with $115M with T cell engagers for chronic immune-mediated disorders. https://lnkd.in/eMGg-q94 🤝 Merus N.V. and Biohaven to co-develop three novel bispecific ADC programs. https://lnkd.in/eKtQW5Xi 💰 Eli Lilly and Company offers $99M licensing agreement for Mediar Therapeutics’ WISP1 antibody for pulmonary fibrosis. https://lnkd.in/et-eBTUJ 💸 Normunity closes $75M Series B financing to advance T cell engager candidate for solid tumors. https://lnkd.in/eP-Ca5R3 #Biointron #Antibodies #Immunotherapy #PharmaNews #Healthcare #DrugDevelopment #DrugDiscovery #Oncology #Innovation #Networking

In business news, Surrozen, Inc. announced a strategic research collaboration with privately-held TCGFB, Inc. to discover antibody therapeutics targeting Transforming Growth Factor Beta (TGF-β) for the potential treatment of patients with idiopathic pulmonary fibrosis. Under the terms of the agreement, Surrozen will provide antibody discovery services for a period of up to two years. TCGFB will own all TGF-β product related intellectual property. In exchange for Surrozen’s research services, TCGFB will pay Surrozen up to $6 million in the aggregate, plus any third-party costs, and will issue Surrozen a warrant for up to 3,380,000 shares of TCGFB common stock at an exercise price of $0.0001 per share based on certain vesting conditions. #mabs https://lnkd.in/e5mgqDc4

In 2006, during a first-in-human study with TGN1412 (a CD28-specific superagonist mAb), a life-threatening cytokine release syndrome occurred. This event prompted recommendations to enhance safety in initial human clinical trials with mAbs. Hansel et a. take a closer look at the safety and side effects of currently available mAbs and the advances in preclinical testing and antibody technology aimed at minimizing the risk of these events in this review article, "The safety and side effects of monoclonal antibodies." Measures were taken to identify and minimize potential adverse effects, such as in vitro safety tests on human blood and tissues, predictive tests for CRS on administration to humans, and microdosing. Article link: https://lnkd.in/g2gq-6DC #mab #MonoclonalAntibody #ClincialTrials #DrugDevelopment

Have you registered for our FREE webinar “Empowering Discovery and Development of Bispecific ADCs With a Common Light Chain Antibody Library and a Novel Linker/Payload” yet? Bispecific ADCs, a rising trend in treating solid tumors, promise enhanced efficacy and safety. Crafting them demands meticulous target selection and overcoming challenges like efficient screening and assembly for conjugation. In this webinar, Dr. W. Frank An will discuss the current landscape of bsADCs as a novel therapeutic modality, and introduce Biocytogen's bsADC platform, highlighting the recent progress of several of our bsADC assets. Register Now: https://lnkd.in/ewEi4gJ2 #renbiologics #bsadcs #bispecific #CancerResearch #InnovativeTherapies #antibodydrugconjugates #antibodylibrary #drugdiscovery